Monoclonal Gammopathy of Undetermined Significance

  • Robert A. Kyle
  • S. Vincent Rajkumar
Part of the Contemporary Hematology book series (CH)


Waldenström introduced the term “essential hyperglobulinemia” 55 years ago to describe patients who had a small serum protein electrophoretic spike but no evidence of multiple myeloma (MM), Waldenstrom's macroglobulinemia (WM), primary amyloidosis (AL), or related disorders.<sup>1</sup> Since then, other terms including benign, asymptomatic, idiopathic, nonmyelomatous, and idiopathic paraproteinemia have been used. He stressed the stability of the size of the protein peak and contrasted it with the increasing quantity of the spike in MM. The term “benign monoclonal gammopathy” was also commonly used but it is misleading because some patients will progress to symptomatic MM, WM, AL, or a related monoclonal plasma cell proliferative disorder. The term “monoclonal gammopathy of undetermined significance” (MGUS) was introduced almost 3 decades ago. It was defined as a serum monoclonal (M) protein < 3.0 g/dL; <10% plasma cells in the bone marrow, if performed; little or no M...


Multiple Myeloma Chronic Lymphocytic Leukemia Monoclonal Gammopathies Free Light Chain Serum Protein Electrophoresis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Supported in part by grants (CA 62242 and CA 107476) from the National Cancer Institute.


  1. 1.
    Waldenstrom J. Abnormal proteins in myeloma. Adv Intern Med 1952;5:398–440.PubMedGoogle Scholar
  2. 2.
    Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. [Review] [237 refs]. Immunol Rev 2003;194:112–39.PubMedCrossRefGoogle Scholar
  3. 3.
    Kyle RA. Sequence of testing for monoclonal gammopathies. Arch Pathol Lab Med 1999;123(2):114–8.PubMedGoogle Scholar
  4. 4.
    Keren DF, Alexanian R, Goeken JA, Gorevic PD, Kyle RA, Tomar RH. Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies. Arch Pathol Lab Med 1999;123(2):106–7.PubMedGoogle Scholar
  5. 5.
    Axelsson U, Bachmann R, Hallen J. Frequency of pathological proteins (M-compo nents) om 6,995 sera from an adult population. Acta Med Scand 1966;179(2):235–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972;40(5):719–24.PubMedGoogle Scholar
  7. 7.
    Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol 1982;35(1):63–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly.[erratum appears in Am J Med 1998 Oct;105(4):362]. Am J Med 1998;104(5):439–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Landgren O, Gridley G, Turesson I,et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107(3):904–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopa thy of undetermined significance. N Engl J Med 2006;354(13):1362–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978;64(5):814–26.PubMedCrossRefGoogle Scholar
  12. 12.
    Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ, 3rd. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.[see comment]. Mayo Clin Proc 2004;79(7):859–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Kyle RA, Therneau TM, Rajkumar SV,et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.[see comment]. N Engl J Med 2002;346(8):564–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data CD Rom (1973–1998). In. Bethesda, MD: National Cancer Institute, Cancer Statistitics Branch; 2001.Google Scholar
  15. 15.
    Kyle RA, Linos A, Beard CM,et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989.[see comment]. Blood 1992;79(7):1817–22.PubMedGoogle Scholar
  16. 16.
    Kyle RA, Gertz MA, Witzig TE,. Review of 1027 patients with newly diagnosed multiple myeloma.[see comment]. Mayo Clin Proc 2003;78(1):21–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Axelsson U. A 20-year follow-up study of 64 subjects with M-components. Acta Med Scand 1986;219(5):519–22.PubMedCrossRefGoogle Scholar
  18. 18.
    van de Poel MH, Coebergh JW, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. Br J Haematol 1995;91(1):121–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Baldini L, Guffanti A, Cesana BM,et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996;87(3):912–8.PubMedGoogle Scholar
  20. 20.
    Gregersen H, Ibsen J, Mellemkjoer L, Dahlerup J, Olsen J, Sorensen H. Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 2001;112(2):353–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Ogmundsdottir HM, Haraldsdottir V, Gu mundur MJ,. Monoclonal gammopa thy in Iceland: a population-based registry and follow-up. Br J Haematol 2002;118(1):166–73.PubMedCrossRefGoogle Scholar
  22. 22.
    Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma 2005;6(2):102–14.PubMedCrossRefGoogle Scholar
  23. 23.
    Avet-Loiseau H, Li JY, Facon T,. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998;58(24):5640–5.Google Scholar
  24. 24.
    Avet-Loiseau H, Facon T, Daviet A, 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999;59(18):4546–50.PubMedGoogle Scholar
  25. 25.
    Fonseca R, Bailey RJ, Ahmann GJ,et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002;100(4):1417–24.PubMedGoogle Scholar
  26. 26.
    Chng WJ, Van Wier SA, Ahmann GJ,et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005;106(6):2156–61.PubMedCrossRefGoogle Scholar
  27. 27.
    Avet-Loiseau H, Li JY, Morineau N, Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood 1999;94(8):2583–9.PubMedGoogle Scholar
  28. 28.
    Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IMS. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005;105(1):317–23.PubMedCrossRefGoogle Scholar
  29. 29.
    Takahashi T, Shivapurkar N, Reddy J,et al. DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 2004;10(9):2928–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Rajkumar SV, Mesa RA, Fonseca R,et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8(7):2210–6.PubMedGoogle Scholar
  31. 31.
    Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angio-genesis inhibitory activity with disease progression. Blood 2004;104(4):1159–65.PubMedCrossRefGoogle Scholar
  32. 32.
    Melton LJ, 3rd, Rajkumar SV, Khosla S,et al. Fracture risk in monoclonal gam mopathy of undetermined significance. J Bone Miner Res 2004;19(1):25–30.PubMedCrossRefGoogle Scholar
  33. 33.
    Roodman GD, III. Biology of myeloma bone disease. In: Broudy VC, Abkowitz JL, Vose JM, eds. Hematology 2002: American Society of Hematology Education Program Book. Washington, DC; 2002:227–32.Google Scholar
  34. 34.
    Croucher PI, Shipman CM, Lippitt J,et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98(13):3534–40.PubMedCrossRefGoogle Scholar
  35. 35.
    Lust JA, Donovan KA. Biology of the transition of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma. Cancer Control 1998;5(3):209–17.PubMedGoogle Scholar
  36. 36.
    Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol 2002;97(6):1371–4.PubMedCrossRefGoogle Scholar
  37. 37.
    Rajkumar SV, Kyle RA, Plevak MF, Murray JA, Therneau TM. Helicobacter pylori infection and monoclonal gammopathy of undetermined significance. Br J Haematol 2002;119(3):706–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Kyle RA. “Benign” monoclonal gammopathy–after 20 to 35 years of follow-up. Mayo Clin Proc 1993;68(1):26–36.PubMedGoogle Scholar
  39. 39.
    Blade J, Lopez-Guillermo A, Rozman C,et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992;81(3):391–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Cesana C, Klersy C, Barbarano L,et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002;20(6):1625–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Rajkumar SV, Kyle RA, Therneau TM,. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106(3):812–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Kumar S, Rajkumar SV, Kyle RA,et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005;23(24):5668–74.PubMedCrossRefGoogle Scholar
  43. 43.
    Ocqueteau M, Orfao A, Almeida J, Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152(6):1655–65.PubMedGoogle Scholar
  44. 44.
    Garewal H, Durie BG, Kyle RA, Finley P, Bower B, Serokman R. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 1984;2(1):51–7.PubMedGoogle Scholar
  45. 45.
    Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121(5):749–57.Google Scholar
  46. 46.
    Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980;302(24):1347–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacy toma of bone and asymptomatic multiple myeloma. Blood 2000;96(6):2037–44.PubMedGoogle Scholar
  48. 48.
    Rosinol L, Blade J, Esteve J,et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003;123(4):631–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Kyle RA, Remstein ED, Therneau TM,et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356(25):2582–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I–a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993;50(2):95–102.PubMedCrossRefGoogle Scholar
  51. 51.
    Grignani G, Gobbi PG, Formisano R, et al. A prognostic index for multiple myeloma. Br J Cancer 1996;73(9):1101–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Rajkumar SV, Gertz MA, Lacy MQ,. Thalidomide as initial therapy for early-stage myeloma.[see comment]. Leukemia 2003;17(4):775–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of biclonal gammopa thies. Review of 57 cases. Am J Med 1981;71(6):999–1008.PubMedCrossRefGoogle Scholar
  54. 54.
    Grosbois B, Jego P, de Rosa H, Triclonal gammopathy and malignant immunoprolif erative syndrome. [Review] [25 refs] [French]. Rev Med Interne 1997; 18(6):470–3.PubMedCrossRefGoogle Scholar
  55. 55.
    Tirelli A, Guastafierro S C a v a B Lucivero G. Triclonal gammopathy in an extran odal non-Hodgkin lymphoma patient. Am J Hematol 2003;73(4):273–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Kyle RA, Maldonado JE, Bayrd ED. Idiopathic Bence Jones proteinuria–a distinct entity? Am J Med 1973;55(2):222–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Kyle RA, Greipp PR. “Idiopathic” Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 1982;306(10):564–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Kyle RA, Garton JP. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 1987;62(8):719–31.PubMedGoogle Scholar
  59. 59.
    Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance ? Clin Cancer Res 2005;11(5):1786–90.PubMedCrossRefGoogle Scholar
  60. 60.
    Kyle RA, Therneau TM, Rajkumar SV,. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102(10):3759–64.PubMedCrossRefGoogle Scholar
  61. 61.
    Morra E, Cesana C, Klersy C, et al. Prognostic factors for transformation in asymptomatic immunoglobulin m monoclonal gammopathies. Clin Lymphoma 2005;5(4):265–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Cesana C, Barbarano L, Miqueleiz S, et al. Clinical characteristics and outcome of immunoglobulin M-related disorders. Clin Lymphoma 2005;5(4):261–4.PubMedCrossRefGoogle Scholar
  63. 63.
    Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopa thies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005;23(21):4662–8.PubMedCrossRefGoogle Scholar
  64. 64.
    O'Connor ML, Rice DT, Buss DH, Muss HB. Immunoglobulin D benign monoclonal gammopathy. A case report. [Review] [16 refs]. Cancer 1991;68(3):611–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Blade J, Kyle RA. IgD monoclonal gammopathy with long-term follow-up. Br J Haematol 1994;88(2):395–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. In: Malpas J,,eds. Myeloma: Biology and Management, 3rd Ed. Philadelphia, PS: Saunders; 2004:315–52.Google Scholar
  67. 67.
    Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006;134(6):573–89.PubMedCrossRefGoogle Scholar
  68. 68.
    Azar HA, Hill WT, Osserman EF. Malignant lymphoma and lymphatic leukemia. Am J Med 1957;23:239–49.PubMedCrossRefGoogle Scholar
  69. 69.
    Kyle RA, Bayrd ED, McKenzie BF, Heck FJ. Diagnostic Criteria for electro-phoretic patterns of serum and urinary proteins in multiple myeloma: study of one hundred and sixty-five multiple myeloma patients with similar electrophoretic patterns. JAMA 1960;174:245–51.PubMedGoogle Scholar
  70. 70.
    Alexanian R. Monoclonal gammopathy in lymphoma. Arch Intern Med 1975;135(1):62–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros LJ. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol 2005;123(2):200–5.PubMedCrossRefGoogle Scholar
  72. 72.
    Asatiani E, Cohen P, Ozdemirli M, Kessler CM, Mavromatis B, Cheson BD. Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. Am J Hematol 2004;77(2):144–6.PubMedCrossRefGoogle Scholar
  73. 73.
    Noel P, Kyle RA. Monoclonal proteins in chronic lymphocytic leukemia. Am J Clin Pathol 1987;87(3):385–8.PubMedGoogle Scholar
  74. 74.
    Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005;105(12):4569–72.PubMedCrossRefGoogle Scholar
  75. 75.
    Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 2005;34(3):197–200.PubMedCrossRefGoogle Scholar
  76. 76.
    Lamboley V, Zabraniecki L, Sie P, Pourrat J, Fournie B. Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review. Joint, Bone, Spine: Revue du Rhumatisme 2002;69(1):62–7.CrossRefGoogle Scholar
  77. 77.
    Sallah S, Husain A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004;15(10):1490–4.PubMedCrossRefGoogle Scholar
  78. 78.
    Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopa-thies of undetermined significance.[see comment]. Ann Neurol 1991;30(1):54–61.PubMedCrossRefGoogle Scholar
  79. 79.
    Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy asso ciated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325(21):1482–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol 2006;63(8):1066–71.PubMedCrossRefGoogle Scholar
  81. 81.
    Nobile-Orazio E. Treatment of dys-immune neuropathies. J Neurol 2005;252(4):385–95PubMedCrossRefGoogle Scholar
  82. 82.
    Hadden RD, Nobile-Orazio E, Sommer C, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13(8):809–18.PubMedCrossRefGoogle Scholar
  83. 83.
    European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006;11(1):9–19.Google Scholar
  84. 84.
    Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long term outcome. Blood 2003;101(7):2496–506.PubMedCrossRefGoogle Scholar
  85. 85.
    Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the litera ture. Blood 2004;104(10):3400–7.PubMedCrossRefGoogle Scholar
  86. 86.
    Mundis RJ, Kyle RA. Primary hyperparathyroidism and monoclonal gammopathy of undetermined significance. Am J Clin Pathol 1982;77(5):619–21.PubMedGoogle Scholar
  87. 87.
    Arnulf B, Bengoufa D, Sarfati E,. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study. Arch Intern Med 2002;162(4):464–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Daoud MS, Lust JA, Kyle RA, Pittelkow MR. Monoclonal gammopathies and asso ciated skin disorders. [Review] [214 refs]. J Am Acad Dermatol 1999;40(4):507–35; quiz 36–8.CrossRefGoogle Scholar
  89. 89.
    Zent CS, Wilson CS, Tricot G, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998;91(9):3518–23.PubMedGoogle Scholar
  90. 90.
    Rostaing L, Modesto A, Abbal M, Durand D. Long-term follow-up of monoclonal gammopathy of undetermined significance in transplant patients. Am J Nephrol 1994;14(3):187–91.PubMedCrossRefGoogle Scholar
  91. 91.
    Pascual M, Mach-Pascual S, Schifferli JA. Paraproteins and complement depletion: pathogenesis and clinical syndromes. Semin Hematol 1997;34(1 Suppl 1):40–8.PubMedGoogle Scholar
  92. 92.
    Droder RM, Kyle RA, Greipp PR. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med 1992;92(5):523–6.PubMedCrossRefGoogle Scholar
  93. 93.
    Dingli D, Larson DR, Plevak MF, Grande JP, Kyle RA. Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis 2005;46(2):278–82.PubMedCrossRefGoogle Scholar
  94. 94.
    Karlson EW, Tanasijevic M, Hankinson SE,. Monoclonal gammopathy of undetermined significance and exposure to breast implants. Arch Intern Med 2001;161(6):864–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Merlini G, Farhangi M, Osserman EF. Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. [Review] [202 refs]. Semin Oncol 1986;13(3):350–65.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Robert A. Kyle
    • 1
  • S. Vincent Rajkumar
    • 1
  1. 1.Mayo ClinicRochesterUSA

Personalised recommendations